Literature DB >> 11544321

Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides.

I Gursel1, M Gursel, K J Ishii, D M Klinman.   

Abstract

Immunostimulatory CpG oligonucleotides (ODN) show promise as immune adjuvants, anti-allergens, and immunoprotective agents. Increasing the bioavailability and duration of action of CpG ODN should improve their therapeutic utility. Encapsulating ODN in sterically stabilized cationic liposomes provides protection from serum nucleases while facilitating uptake by B cells, dendritic cells, and macrophages. In a pathogen challenge model, sterically stabilized cationic liposomes encapsulation doubled the duration of CpG ODN-induced immune protection. In an immunization model, coencapsulation of CpG ODN with protein Ag (OVA) magnified the resultant Ag-specific IFN-gamma and IgG responses by 15- to 40-fold compared with Ag plus CpG ODN alone. These findings support the use of sterically stabilized cationic liposomes to significantly enhance the therapeutic efficacy of CpG ODN.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11544321     DOI: 10.4049/jimmunol.167.6.3324

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge.

Authors:  Christopher H Logue; Aaron T Phillips; Eric C Mossel; Jeremy P Ledermann; Thomas Welte; Steve W Dow; Ken E Olson; Ann M Powers
Journal:  Antiviral Res       Date:  2010-05-07       Impact factor: 5.970

Review 2.  Liposome-nucleic acid immunotherapeutics.

Authors:  Steven Dow
Journal:  Expert Opin Drug Deliv       Date:  2008-01       Impact factor: 6.648

3.  Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model.

Authors:  Alyssa L Siefert; Allison Ehrlich; María Jesús Corral; Karen Goldsmith-Pestana; Diane McMahon-Pratt; Tarek M Fahmy
Journal:  Biomaterials       Date:  2016-09-06       Impact factor: 12.479

4.  A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide delivery.

Authors:  Xiaojuan Yang; Yong Peng; Bo Yu; Jianhua Yu; Chenguang Zhou; Yicheng Mao; L James Lee; Robert J Lee
Journal:  Mol Pharm       Date:  2011-03-23       Impact factor: 4.939

5.  Cationic Liposome-Oligonucleotide Complex as an Alternative Adjuvant for Polyclonal Antibody Production in New Zealand White Rabbits (Oryctolaguscuniculus).

Authors:  Erin S Lee; Clinton Sc Walker; Jacob E Moskowitz; Valerie A Johnson; Lon V Kendall
Journal:  Comp Med       Date:  2017-12-01       Impact factor: 0.982

6.  Antitumor activity of G3139 lipid nanoparticles (LNPs).

Authors:  Xiaogang Pan; Li Chen; Shujun Liu; Xiaojuan Yang; Jian-Xin Gao; Robert J Lee
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

7.  A novel vaccine adjuvant for recombinant flu antigens.

Authors:  Stella Chang; John Warner; Lily Liang; Jeff Fairman
Journal:  Biologicals       Date:  2009-03-12       Impact factor: 1.856

8.  Efficacy of cationic lipid-DNA complexes (CLDC) on hepatitis B virus in transgenic mice.

Authors:  John D Morrey; Neil E Motter; Brandon Taro; Marla Lay; Jeffery Fairman
Journal:  Antiviral Res       Date:  2008-02-25       Impact factor: 5.970

9.  Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis.

Authors:  Ryan M Troyer; Katie L Propst; Jeff Fairman; Catherine M Bosio; Steven W Dow
Journal:  Vaccine       Date:  2009-05-31       Impact factor: 3.641

10.  Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Jane E Strasser; Nicholas Farley; Claudia Chalk; Marla Lay; Jeff Fairman
Journal:  Clin Vaccine Immunol       Date:  2009-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.